Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
The presentation of ICI pneumonitis is highly variable, and outcomes are dependent on severity, but favor grade 2 disease when patients are rechallenged with immunotherapy. However, using commonly available clinical data, we can accurately identify patients at high risk of death from ICI pneumonitis. Further effort is needed to produce clinical models able to provide clinician decision support when evaluating patients with ICI toxicities and considering ICI rechallenge.
Authors
- Gordon Ruan (ORCID: https://orcid.org/0000-0002-6969-9169)
- Robert Haemmerle (ORCID: https://orcid.org/0000-0003-0139-9706)
- Irene Riestra Guiance (ORCID: https://orcid.org/0000-0002-0438-6567)
- Casey Fazer-Posorske (ORCID: https://orcid.org/0000-0001-7417-030X)
- Konstantinos Leventakos (ORCID: https://orcid.org/0000-0001-9784-8603)
- Richard Curtis Godby (ORCID: https://orcid.org/0000-0001-6362-1638)
- Allison LeMahieu (ORCID: https://orcid.org/0000-0003-1554-795X)
- Keith Mcconn (ORCID: https://orcid.org/0000-0002-5802-473X)
- Jacob Shreve (ORCID: https://orcid.org/0000-0003-4897-6961)
- Lisa A. Kottschade (ORCID: https://orcid.org/0000-0001-8922-2619)
- Antonious Hazim (ORCID: https://orcid.org/0000-0003-2938-3730)
- Ashley Egan
- Eric S. Edell (ORCID: https://orcid.org/0009-0003-7286-1416)
- Tobias Peikert
- Damian McGlothlin
- Anna Schwecke
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1007/s00262-025-04053-9
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.32